James Edgemond Sells 10,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of the stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $547.50, for a total transaction of $5,475,000.00. Following the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at $10,334,610. This represents a 34.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

James Edgemond also recently made the following trade(s):

• On Thursday, June 4th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $546.28, for a total transaction of $5,462,800.00.
• On Monday, June 1st, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $547.87, for a total transaction of $5,478,700.00.
• On Thursday, May 28th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $565.63, for a total transaction of $5,656,300.00.
• On Tuesday, May 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $572.94, for a total transaction of $5,729,400.00.
• On Thursday, May 21st, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $564.11, for a total transaction of $5,641,100.00.
• On Monday, May 18th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $567.31, for a total transaction of $5,673,100.00.
• On Thursday, May 14th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $574.47, for a total transaction of $5,744,700.00.
• On Monday, May 11th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $573.03, for a total transaction of $5,730,300.00.
• On Thursday, May 7th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $578.58, for a total transaction of $5,785,800.00.
• On Monday, May 4th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $576.93, for a total transaction of $5,769,300.00.

United Therapeutics Trading Down 1.6%

Shares of United Therapeutics stock opened at $544.10 on Thursday. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35. The company has a market cap of $23.10 billion, a price-to-earnings ratio of 20.08, a PEG ratio of 1.80 and a beta of 0.57. The company’s 50-day moving average price is $568.19 and its 200-day moving average price is $520.67.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. During the same period in the previous year, the company posted $6.63 earnings per share. The company’s quarterly revenue was down 1.6% compared to the same quarter last year. On average, sell-side analysts predict that United Therapeutics Corporation will post 26.84 earnings per share for the current year.

Institutional Investors Weigh In On United Therapeutics

Hedge funds have recently bought and sold shares of the stock. Leuthold Group LLC lifted its stake in United Therapeutics by 41.4% in the fourth quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock worth $5,200,000 after acquiring an additional 3,126 shares during the period. Tobam lifted its stake in United Therapeutics by 183.9% in the third quarter. Tobam now owns 7,646 shares of the biotechnology company’s stock worth $3,205,000 after acquiring an additional 4,953 shares during the period. UBS Group AG lifted its stake in United Therapeutics by 45.3% in the fourth quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock worth $110,045,000 after acquiring an additional 70,445 shares during the period. Perpetual Ltd purchased a new stake in United Therapeutics in the fourth quarter worth $1,059,000. Finally, SG Americas Securities LLC lifted its stake in United Therapeutics by 88.6% in the fourth quarter. SG Americas Securities LLC now owns 26,960 shares of the biotechnology company’s stock worth $13,136,000 after acquiring an additional 12,663 shares during the period. 94.08% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on UTHR shares. Morgan Stanley set a $516.00 price target on shares of United Therapeutics in a report on Thursday, May 7th. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Raymond James Financial assumed coverage on shares of United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price on the stock. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Finally, UBS Group lifted their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.